Centessa Pharmaceuticals plc
Common Stock · USD · NASDAQ
Price
$39.76
Cap
—
Earnings
—
30d Trend
+0.7%
70% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 60×Macro 0.99 (−1%)=59
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
6-9 month momentum thesis — strong trend with confirmation
BRAIN47'S ASSESSMENT
I rate Centessa Pharmaceuticals plc at 59/100 — a STRONG reading on the Brain47 Signal. The strongest factor is momentum at 88/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
+0.8%
3 MONTHS
+48.1%
12 MONTHS
+207.1%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
6-9 month momentum thesis — strong trend with confirmation. Momentum (88) and Technical (54) are the primary strengths. I note that quality is the weakest area at 44/100 — this warrants monitoring. Historical volatility is elevated at 70%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.